CD44 as a prognostic and predictive marker for GBM.

Authors:
  • BVB. D. Vaillant
    B. D. Vaillant
  • KBK. Bhat
    K. Bhat
  • ESE. P. Sulman
    E. P. Sulman
  • VBV. Balasubramaniyan
    V. Balasubramaniyan
  • SWS. Wang
    S. Wang
  • KAK. D. Aldape
    K. D. Aldape
  • HCH. Colman
    H. Colman

Abstract
2049 Background: While GBM has a poor prognosis overall, molecular subsets of tumors exist with differential outcome to initial treatment. Finding biomarkers of outcome would be beneficial prognostically and help understand resistance mechanisms. Previous GBM molecular subtyping demonstrated that the mesenchymal GBM subtype has worse prognosis compared to tumors with a proneural signature. CD44 is a cell surface marker associated with cancer stem cell populations and treatment resistance in other tumors. Methods: We performed expression profiling analyses of multiple GBM stem cell (GSC) lines derived from individual human tumors. GSCs were subjected to in vitro radiation (2Gy) and invasion assayed by matrigel assay. We analyzed 3 GBM gene expression datasets (TCGA, Rembrandt, Erasmus) for CD44 correlation with other genes and survival. We performed semi-quantitative immunohistochemistry for CD44 on a retrospective set of GBM tumors. Results: CD44 expression was significantly higher in GSCs with a mesenchy...